Care delivery, health software, and medical technology — private healthcare ranked by latest disclosed valuation.
| # | Company | Valuation | Secondary $/sh | vs Last Round | Last Round | IPO Status |
|---|---|---|---|---|---|---|
| 1 | Devoted Health Waltham, MA |
$13Bmark 2023-Q4 | $35.51as of 2026-06-27 | -36.9% | Series F-Prime · 2026-01-30 · $317M | rumored |
| 2 | OpenEvidence Miami, FL |
$12Bmark 2026-Q1 | $454.21as of 2026-06-27 | -6.8% | Series D · 2026-01-21 · $250M | private |
| 3 | Oura Oulu, Finland |
$11Bmark 2026-08 | no secondary mark | — | Series E · 2025-10-14 · $900M | rumored |
| 4 | Neuralink Fremont, California |
$9.0Bmark 2026-08 | no secondary mark | — | Series E · 2025-06-01 · $650M | none |
| 5 | Ro New York, NY |
$7.0Bmark 2025 | no secondary mark | — | Series D · 2022-02-22 · $150M | rumored |
| 6 | Commure Mountain View, CA |
$7.0Bmark 2026-05 | $27.57as of 2026-06-27 | no priced round on record | undisclosed | private |
| 7 | Zipline South San Francisco, California |
$6.9Bmark 2026-Q1 | $70.76as of 2026-06-27 | no priced round on record | Series H · 2026-03-22 · $800M | Private |
| 8 | WeDoctor Hangzhou, China |
$6.9Bmark 2020-Q4 | no secondary mark | = last roundmark | Series F · 2020-12-17 · $411M | private |
| 9 | WHOOP Boston, Massachusetts |
$6.7Bmark 2026-Q1 | $7.15as of 2026-06-27 | -36.3% | Series G-2 · 2026-03-30 · $47M | Private |
| 10 | Ro Health New York, NY |
$6.6Bmark 2022-Q1 | $5.46as of 2026-06-27 | -64.4% | Later Stage VC · 2022-01-12 · $150M | private |
| 11 | Benchling San Francisco, USA |
$6.1Bmark 2021-Q4 | no secondary mark | — | Series F · 2021-11-18 · $100M | rumored |
| 12 | Lark Singapore, Singapore |
$6.0Bmark 2026-05 | $4.00as of 2026-06-27 | -74.1% | Series D · 2024-09-30 · $16M | private |
| 13 | Lyra Health Burlingame, CA |
$5.9Bmark 2024-07 | no secondary mark | — | Funding round · 2024 · $200M | private |
| 14 | Alan Paris, France |
$5.9Bmark 2026-Q1 | $14.60as of 2026-06-27 | = last roundmark | Later Stage VC · 2026-03-11 · $118M | private |
| 15 | Abridge Pittsburgh, Pennsylvania |
$5.7Bmark 2025-Q2 | $182.57as of 2026-06-27 | +15.2% | Series E · 2025-06-23 · $300M | Private |
| 16 | Verily Dallas, TX |
$5.0Bmark 2026-Q1 | no secondary mark | — | Strategic recapitalization · 2026-03-19 · $300M | no imminent plans |
| 17 | PointClickCare Toronto, Canada |
$5.0Bmark 2024-05 | no secondary mark | +25.0%mark | Private Equity · 2018-02-28 · $146M | private |
| 18 | Cerebral Claymont, DE |
$4.8Bmark 2021-Q4 | $2.55as of 2026-06-27 | = last roundmark | Series C · 2021-12-07 · $300M | private |
| 19 | Reify Health Boston, MA |
$4.8Bmark 2022-Q1 | no secondary mark | = last roundmark | Series D · 2022-01-07 · $217M | private |
| 20 | Color Burlingame, CA |
$4.6Bmark 2021-Q4 | $12.24as of 2026-06-27 | -87.8% | Series E · 2021-11-08 · $100M | private |
| 21 | Sword Health New York, NY |
$4.5Bmark 2025-Q2 | $27.83as of 2026-06-27 | -61.1% | Series F · 2025-06-17 · $40M | private |
| 22 | Medlinker Chengdu, China |
$4.0Bmark 2020-Q4 | no secondary mark | = last roundmark | Series E · 2020-12-31 · $514M | private |
| 23 | Doctolib Levallois-Perret, France |
$3.8Bmark 2026-02 | no secondary mark | -41.3%mark | Series F · 2022-03-14 · $557M | private |
| 24 | Noom New York, NY |
$3.7Bmark 2024-Q2 | $2.98as of 2026-06-27 | no priced round on record | Series F · 2021-05-25 · $540M | rumored |
| 25 | Ultima Genomics Fremont, CA |
$3.6Bmark 2022-Q2 | $24.96as of 2026-06-27 | -50.2% | Series E · 2022-05-31 · $229M | private |
| 26 | Hippocratic AI Palo Alto, CA |
$3.5Bmark 2025-11 | $26.33as of 2026-06-27 | 0.0% | Series C · 2025-11-01 · $141M | no imminent plans |
| 27 | Everly Health Austin, TX |
$3.5Bmark 2021-Q1 | $16.14as of 2026-06-27 | -75.0% | Series F · 2021-03-23 · $154M | private |
| 28 | Spring Health New York, NY |
$3.3Bmark 2024-Q3 | $31.24as of 2026-06-27 | -54.0% | Series E · 2024-07 · $100M | private |
| 29 | Komodo Health New York, NY |
$3.3Bmark 2021-Q1 | $13.86as of 2026-06-27 | -72.8% | Series E · 2021-03-21 · $220M | private |
| 30 | Judi Health New York, NY |
$3.3Bmark 2025-Q3 | $15.12as of 2026-06-27 | +12.1% | Series F · 2025-09-08 · $400M | private |
| 31 | Cedar New York, NY |
$3.2Bmark 2021-Q2 | $23.55as of 2026-06-27 | = last roundmark | Later Stage VC · 2021-06-16 · $268M | private |
| 32 | Headspace Santa Monica, CA |
$3.0Bmark 2021-Q3 | $4.43as of 2026-06-27 | +47.7% | Merger (Headspace + Ginger) · 2021-08-01 | no imminent plans |
| 33 | Grow Therapy New York, NY |
$3.0Bmark 2026-Q1 | $10.15as of 2026-06-27 | = last roundmark | Series D · 2026-03-03 · $150M | private |
| 34 | CMR Surgical Cambridge, United Kingdom |
$3.0Bmark 2025-Q2 | no secondary mark | = last roundmark | Later Stage VC · 2025-04-02 · $200M | private |
| 35 | OYO Rooms Gurugram, India |
$2.9Bmark 2024-Q3 | $0.25as of 2026-06-27 | -28.6% | Series G · 2024-07-04 · $349M | private |
| 36 | Garner Health | $2.7Bmark 2026-05 | no secondary mark | = last roundmark | Venture · 2026-05 · $100M | Private |
| 37 | Transcarent Denver, CO |
$2.7Bmark 2025-Q2 | $10.38as of 2026-06-27 | -49.3% | Series D1 · 2025-04-06 · $200M | private |
| 38 | Somatus McLean, VA |
$2.6Bmark 2022-Q1 | $800.00as of 2026-06-27 | -8.3% | Series E · 2022-02-23 · $325M | private |
| 39 | Function Health Austin, TX |
$2.5Bmark 2025-Q4 | $60.00as of 2026-06-27 | no priced round on record | Series B · 2025-11-19 · $298M | private |
| 40 | Nourish Sanford, NC |
$2.5Bmark 2026-08 | no secondary mark | +150.0%mark | Series C · 2026-08-01 · $70M | private |
| 41 | DispatchHealth Denver, CO |
$2.4Bmark 2021-Q1 | $904.75as of 2026-06-27 | -22.7% | Series E · 2021-03-03 · $200M | private |
| 42 | Headway New York, NY |
$2.3Bmark 2024-Q3 | $6.95as of 2026-06-27 | -42.1% | Series D · 2024-07 · $100M | private |
| 43 | Strava San Francisco, California |
$2.2Bmark 2025-10 | $9.04as of 2026-06-27 | -35.4% | Series F-1 · 2025-05-21 · $50M | Confidentially filed for IPO |
| 44 | Freenome Brisbane, CA |
$2.2Bmark 2024-Q1 | $1.48as of 2026-06-27 | -80.0% | Later Stage VC · 2024-02-14 · $254M | private |
| 45 | Hotel Engine Denver, CO |
$2.1Bmark 2024-Q3 | $14.34as of 2026-06-27 | -18.6% | Series C · 2024-09-17 · $140M | private |
| 46 | Medable Palo Alto, CA |
$2.1Bmark 2021-Q4 | $3.00as of 2026-06-27 | -69.0% | Series D · 2021-10-24 · $304M | private |
| 47 | Unite Us New York, NY |
$2.1Bmark 2021-Q4 | $58.74as of 2026-06-27 | -76.4% | Series C · 2021-11-17 · $185M | private |
| 48 | Calm San Francisco, USA |
$2.0Bmark 2022-Q1 | $2.17as of 2026-06-27 | -86.3% | Series C · 2022-02-15 · $75M | private |
| 49 | Virta Health Denver, CO |
$2.0Bmark 2024 | no secondary mark | — | Series E · 2021 · $133M | rumored |
| 50 | Noah Medical San Carlos, CA |
$2.0Bmark 2025-Q3 | $5.00as of 2026-06-27 | -57.8% | Series B1 · 2025-09-23 · $230M | private |
vs Last Round — unlabeled: the secondary share price against the round's price per share (the tape's own comparison). print: the latest observed print's implied valuation against the last priced round's post-money. mark: the valuation shown against that post-money — no independent print yet. = last round means the two legs are within 0.5%; for a mark basis that means the valuation shown was set by the round itself. A cell that says no priced round on record has a secondary price but no round to test it against — it is never rendered as 0.
Ranked by tracked Healthcare portfolio companies — counted from disclosed round participation and each firm's notable holdings, so a firm only appears here if it actually holds companies in this ranking. Full capital-side ranking: Top Private Market Investors by AUM.
By latest disclosed valuation, the largest tracked private Healthcare companies are Devoted Health ($13B), OpenEvidence ($12B), Oura ($11B), Neuralink ($9.0B), Ro ($7.0B). The full ranking of 261 companies refreshes daily at quantlogix.ai/private/healthcare.
Ranked by tracked Healthcare portfolio companies, the most active investors are Andreessen Horowitz (11 tracked), Sequoia Capital (8 tracked), General Catalyst (7 tracked), Lightspeed Venture Partners (6 tracked), Thrive Capital (6 tracked). Full ranking: Top Private Market Investors by AUM.
Valuations are each company's latest disclosed mark, dated per row; secondary share prices refresh daily (35 of 261 tracked companies currently carry one). Rows without a usable number say so rather than showing zero.
Methodology. Rankings are by each company's latest disclosed valuation (roster + weekly enrichment); the "mark" chip shows when that valuation was set. Secondary share prices are point estimates from secondary-market activity — one implied price per name, no bid/ask — refreshed daily (marks overlay as of 2026-09-11), each carrying its own date. "vs Last Round" compares the secondary price to the company's own last primary round per-share price; rows without a usable comparison say so rather than showing zero. Companies marked acquired, defunct, or public are excluded. Educational data, not investment advice.